|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
All removed SLNs were examined by conventional PATH and with RT-PCR analysis for the expression of messenger RNA for tyrosinase and the melanoma antigens recognized by T cells.
|
18927334 |
2008 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study analyzes (1) the value of tyrosinase reverse-transcriptase polymerase chain reaction (RT-PCR) of aspirates obtained by ultrasound-guided fine-needle aspiration cytology (US-FNAC) of sentinel nodes (SNs) in patients with melanoma before sentinel lymph node biopsy (SLNB) and (2) the value of RT-PCR of blood samples of all SLNB patients.
|
18981467 |
2008 |
|
Sentinel node (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Patients with melanomas greater than 0.75 mm in tumor thickness participated in a research study that examined their SLNs with routine histology, immunhistochemical staining and a RT-PCR assay based on the tyrosinase probe.
|
18020932 |
2007 |
|
Sentinel node (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Small portions of 54 SLNs from 37 patients undergoing selective lymphadenectomy were subjected to quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR) to quantify messenger RNA (mRNA) transcripts of the following genes: tyrosinase, telomerase, cyclooxygenase-1 (COX-1), COX-2, granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), interferon-gamma (IFN-gamma), IL-4, IL-10 and IL-12.
|
15846142 |
2005 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of this study was to use tyrosinase messenger RNA (mRNA) amplification for the detection of micrometastases in fresh frozen SLNs.
|
15887981 |
2004 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
When the correlation between tyrosinase and/or MIA mRNA expression and disease-free survival was evaluated by the Kaplan-Meier exact test, there was a statistically significant correlation between simultaneous tyrosinase and MIA gene expression in SLNs and progression of disease.
|
15525827 |
2004 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated the role of a single-marker RT-PCR assay for tyrosinase mRNA in the detection of melanoma sentinel lymph node (SLN) metastases and correlated the results with long-term clinical outcome.
|
15459222 |
2004 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Marker expression in histopathologically positive and negative SLNs were as follows: 89%, 92%, 35%, and 43% (positive) and 40%, 33%, 5%, and 13% (negative) for tyrosinase, melanoma antigen recognized by T cells-1, tyrosinase-related protein-1, and tyrosinase-related protein-2, respectively.
|
12913098 |
2003 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
We preserved a portion of each sentinel lymph node (SLN) in liquid nitrogen in the operating room and performed RT-PCR on the specimens to detect the melanoma/melanocyte-specific marker tyrosinase.
|
12595045 |
2003 |
|
Sentinel node (disorder)
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Of these, 88 SNs from 74 patients were submitted to polymerase chain reaction (PCR) in order to detect tyrosinase mRNA.
|
11930111 |
2002 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Specificity of tyrosinase and HMB45 PCR in the detection of melanoma metastases in sentinel lymph node biopsies.
|
12460203 |
2002 |
|
Sentinel node (disorder)
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tyrosinase reverse transcriptase-polymerase chain reaction was applied to search for metastatic melanoma in the sentinel lymph node and in further lymph nodes of a complete lymph node basin in patients who underwent lymph node dissection.
|
10504440 |
1999 |
|
Sentinel node (disorder)
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The detection of tyrosinase mRNA in melanoma SLN specimens by reverse transcription-polymerase chain reaction (RT-PCR) has been reported to be a more sensitive method to detect subclinical metastases, compared with histological analysis.
|
10340881 |
1999 |